Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 30788

Year : 2018 | Month : February | Volume : 12 | Issue : 2 | Page : FE01 - FE05

Lesinurad, a Novel Uricosuric Drug for Allopurinol-Refractory Gout Patients

Yashika Garg, Vishant Gawri, Rajeshwari Gore, Radhe Shyam Garg, Arun Kumar

1. Assistant Professor, Department of Pharmacology, ESIC Dental College and Hospital, New Delhi; Ex-Senior Resident in Pharmacology Department, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi. India. 2. Senior Resident, Department of Orthopaedics, ESIC Medical College and Hospital, Faridabad, Haryana, India. 3. Senior Resident, Department of Pharmacology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, Delhi, India. 4. Professor, Department of Orthopaedics, Government Medical College and Hospital, Amritsar, Punjab, India. 5. Pharmacovigilance Officer, Department of Pharmacology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, Delhi, India.

Correspondence Address :
Dr. Yashika Garg,
Apartment No.174, Agroha Kunj Apartments, Rohini Sector-13, New Delhi-110085, Delhi, India.


Gout is the most common type of arthritis in developed countries that is often inadequately managed. Evidence regarding role of hyperuricaemia in poor outcomes in gout patients (e.g., disability, recurrent hospital admissions) with/without other chronic cardiometabolic comorbidities prompts the search of newer and more effective drugs. Current management of gout is limited to NSAIDS and intra-articular corticosteroids in acute gout and Allopurinol or Febuxostat with or without probenecid in chronic gout. Other drugs used as add-on therapy in refractory cases of gout who fail on monotherapy include benzbromarone and pegloticase but with limited role. Though these drugs have been available for several years, significant proportion of compliant patients fail to achieve consistent control of uric acid levels resulting in acute gout flares. Recent advances in the role of urate transporters in proximal tubules of kidney have resulted in the development of new generation uricosuric drugs including lesinurad. It is recently approved by US Food and Drug Administration (US FDA) and European Medicines Agency (EMA) in patients with uncontrolled gout along with Allopurinol or Febuxostat. Hopefully, it will contribute to fulfill the unmet goals in management of gout.

This review aims at exploring the current therapeutic strategies for the management of chronic gout patients as well as their limitations and the role of Lesinurad in patients who have failed on monotherapy. The published studies and poster presentations were identified by conducting a literature search from electronic database from 1980 till January 2017, using various medical subject headings and terminologies. These studies were screened and publications considered relevant to the topic were included in the study.


Arthritis, Chronic gout, Selective uric acid reabsorption inhibitor

How to cite this article :

Yashika Garg, Vishant Gawri, Rajeshwari Gore, Radhe Shyam Garg, Arun Kumar. LESINURAD, A NOVEL URICOSURIC DRUG FOR ALLOPURINOL-REFRACTORY GOUT PATIENTS. Journal of Clinical and Diagnostic Research [serial online] 2018 February [cited: 2018 Aug 20 ]; 12:FE01-FE05. Available from

DOI and Others

DOI: 10.7860/JCDR/2018/27997.11149

Date of Submission: Mar 03, 2017
Date of Peer Review: Apr 20, 2017
Date of Acceptance: Dec 14, 2017
Date of Publishing: Feb 01, 2018


JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2016: 132.37
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • EBSCOhost
  • Embase & EMbiology
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)